Abstract 1810: Development miR-205-loaded tannic acid-stabilized liposomes for enhanced therapeutic delivery

Abstract Background: The therapeutic potential of microRNAs (miRNAs) in cancer treatment has garnered significant research interest. miR-205 emerging as a promising therapeutic candidate for cancer treatment due to its tumor-suppressive properties. Despite its potential, the clinical translation of miR-205 is hindered by the lack of efficient and scalable delivery systems. Liposomal formulations offer a versatile platform for miRNA delivery, with broad applications in vaccines and anticancer therapies (e.g., mRNA, small molecule drugs). However, challenges such as large-scale production, precise size control, and unform size distribution of lipid-based drug delivery systems remain significant barriers to the widespread use in the pharmaceutical industry. This study aims to develop stable miR-205 liposome formulations for cancer therapeutics. Methods: A microfluidics chip-based platform, leveraging commercially available microfluidic device technology, was employed to synthesize miR-205-loaded liposomes. Liposomes were produced at a total flow rate (TFR) of 10 ml/min and a flow rate ratio (FRR) of 1:3. The effect of key formulation parameters, including TFR, FRR, and total lipid concentration, on particle size and size distribution, was systematically investigated. Liposomes were also produced using a conventional method for comparative analysis. The formulations were characterized for their physiochemical properties using dynamic light scattering (DLS) and Fourier-transform infrared spectroscopy (FTIR), and their stability. The cell viability of endometrial cell lines treated with different concentrations of liposome were assessed by 3-(4, 5-Dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) assay and cell counting. Cell migration was evaluated using wound-healing assay. Results: All liposomal formulations displayed an average particle size below 200 nm with acceptable physicochemical stability and a low polydispersity index (PDI). The microfluidic approach demonstrated superior control over liposome size and PDI compared to traditional bulk methods, highlighting its potential for scalable and reproducible production. Furthermore, miR-205-loaded liposomes produced via microfluidics exhibited robust encapsulation efficiency and effective intracellular delivery of miR-205 in cancer cell models. The in vitro functional assays confirm superior anti-cancer potential in cancer cells. Conclusions: This study highlights the potential of microfluidic platforms as a scalable and efficient technology for manufacturing of liposomal formulation. The miR-205-loaded liposomes developed in this study showed significant promise in delivering therapeutic miRNAs to cancer cells, demonstrating the feasibility of this platform for clinical translation. Citation Format: Victoria Herrera, Rahul Tiwari, Bridgette Lozano, Neeraj Chauhan, E N Kumar Ghali, Subhash Chauhan, Murali Yallapu. Development miR-205-loaded tannic acid-stabilized liposomes for enhanced therapeutic delivery [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 1810.